Bayer’s heart failure drug bound for NHS on NICE recommendation
The UK’s National Institute for Health and Care Excellence (NICE) has recommended Bayer’s non-steroidal heart failure drug, Kerendia (finerenone), for…
All articles by Annabel Kartal Allen
Annabel Kartal Allen
Annabel Kartal-Allen is a reporter for Clinical Trials Arena, Pharmaceutical Technology and Medical Device Network based in London, UK. Annabel holds interests in oncology, neurology and metabolic diseases. She has previous experience reporting for both the pharmaceutical and nutraceutical industries, and holds a BSc in Biology from the University of Sussex. Contact Annabel
-
-
Lilly enters psychedelic realm through $2.8bn AtaiBeckley takeover
Following its high-profile dealmaking spree in the first portion of 2026, Eli Lilly has struck again – this time through…
-
Big pharma-backed AdvanCell pockets $315m to progress RLT to Phase III
Radiopharmaceutical specialist AdvanCell has banked $315m in an upsized Series D financing to take its prostate cancer therapy to registrational…
-
AAIC26: The role of biomarkers in primary care and early diagnostics
In recent years, there have been several core developments within the Alzheimer’s space – including the debut of the first…
-
Podcast: Patient advocates join the blood cancer ASCT vs CAR-T debate
In recent years, there has been strong discourse in the blood cancer space around the best way to treat patients…
-
Bayer banks €3bn in Apollo contraceptives division deal
Bayer has sold a stake in its newly established contraceptives offshoot to global asset management firm Apollo for €3bn ($3.4bn)…
-
Ipsen set to rival Botox after duo of Phase III migraine wins
Ipsen Pharmaceuticals’ Dysport (abobotulinumtoxinA), a Botox (onabotulinumtoxinA) competitor, could be on track for a label expansion after the drug posted…
-
FDA cracks down on illegal ketamine sellers amid nearing ‘psychedelic revolution’
The US Food and Drug Administration’s (FDA’s) drug review agency has initiated a crackdown on e-commerce sites selling illicit ketamine…
-
Kalohexis confidentially files IPO to back obesity and cachexia portfolio
Metabolic health-focused drug developer Kalohexis is eyeing a debut on the public market after confidentially filing for an initial public…
-
Roche pens $490m Astex breast cancer license deal
Roche has taken fresh steps to uphold its breast cancer legacy defined by Herceptin (trastuzumab) and Perjeta (pertuzumab), as its…